BioXcel Therapeutics Inc (BTAI)
2.61
0.00 (0.00%)
USD |
NASDAQ |
Apr 26, 16:00
2.61
0.00 (0.00%)
After-Hours: 20:00
BioXcel Therapeutics Enterprise Value: 115.18M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 115.18M |
| April 24, 2024 | 118.24M |
| April 23, 2024 | 126.19M |
| April 22, 2024 | 122.52M |
| April 19, 2024 | 119.46M |
| April 18, 2024 | 113.35M |
| April 17, 2024 | 114.57M |
| April 16, 2024 | 117.32M |
| April 15, 2024 | 119.46M |
| April 12, 2024 | 124.05M |
| April 11, 2024 | 120.69M |
| April 10, 2024 | 115.79M |
| April 09, 2024 | 113.96M |
| April 08, 2024 | 115.79M |
| April 05, 2024 | 116.71M |
| April 04, 2024 | 117.63M |
| April 03, 2024 | 116.10M |
| April 02, 2024 | 116.10M |
| April 01, 2024 | 121.60M |
| March 28, 2024 | 121.60M |
| March 27, 2024 | 123.44M |
| March 26, 2024 | 122.83M |
| March 25, 2024 | 122.52M |
| March 22, 2024 | 121.30M |
| March 21, 2024 | 121.91M |
| Date | Value |
|---|---|
| March 20, 2024 | 120.38M |
| March 19, 2024 | 118.55M |
| March 18, 2024 | 119.16M |
| March 15, 2024 | 116.80M |
| March 14, 2024 | 122.57M |
| March 13, 2024 | 122.57M |
| March 12, 2024 | 119.53M |
| March 11, 2024 | 123.48M |
| March 08, 2024 | 130.17M |
| March 07, 2024 | 127.74M |
| March 06, 2024 | 125.31M |
| March 05, 2024 | 127.13M |
| March 04, 2024 | 130.17M |
| March 01, 2024 | 132.90M |
| February 29, 2024 | 131.99M |
| February 28, 2024 | 134.73M |
| February 27, 2024 | 136.24M |
| February 26, 2024 | 129.56M |
| February 23, 2024 | 128.65M |
| February 22, 2024 | 131.69M |
| February 21, 2024 | 131.08M |
| February 20, 2024 | 142.02M |
| February 16, 2024 | 142.02M |
| February 15, 2024 | 144.45M |
| February 14, 2024 | 129.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.79M
Minimum
Nov 07 2019
1.364B
Maximum
Feb 11 2021
428.43M
Average
325.61M
Median
Mar 23 2020
Enterprise Value Benchmarks
| Synlogic Inc | -26.08M |
| Cormedix Inc | 209.32M |
| Bristol-Myers Squibb Co | 117.94B |
| Verastem Inc | 136.17M |
| Ocular Therapeutix Inc | 503.35M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.26M |
| Revenue (Quarterly) | 0.376M |
| Total Expenses (Quarterly) | 20.25M |
| EPS Diluted (Quarterly) | -0.75 |
| Gross Profit Margin (Quarterly) | -89.89% |
| Profit Margin (Quarterly) | -5.92K% |
| Earnings Yield | -235.2% |
| Normalized Earnings Yield | -229.80 |